Quanterix

What Quanterix does

Quanterix Corporation is a publicly traded precision biomarker science company (Nasdaq: QTRX) founded in 2007 and headquartered in Billerica, Massachusetts. The company develops and commercializes the proprietary Simoa (Single Molecule Array) digital immunoassay platform, which enables detection of protein biomarkers at single-molecule resolution — up to 1,000x more sensitive than conventional ELISA methods — and supports a portfolio of instruments including the HD-X Analyzer, SR-X Biomarker Detection System, and SP-X Imaging and Analysis System. Through the July 2025 $286 million merger with Akoya Biosciences, Quanterix added a complementary spatial biology platform comprising the PhenoCycler-Fusion and PhenoImager HT instruments plus a suite of PhenoCode assay panels and supporting software (phenoptr, inForm, Phenochart), creating a dual-modality business spanning liquid biomarkers and tissue-based analysis.

Quanterix monetizes through a three-stream model: (1) instrument placements generating an installed base of 2,300+ systems globally, (2) recurring consumables and reagents that account for approximately 75% of revenue, and (3) laboratory services via the Accelerator Laboratory offering custom assay development and contract research. Target customers include pharmaceutical and biotech companies, academic and research institutions, contract research organizations, and clinical diagnostics providers. The Lucent Diagnostics subsidiary operates the LucentAD Complete multi-analyte blood test for Alzheimer's disease detection, which carries a $897 CMS reimbursement rate, FDA Breakthrough Device Designation, a pending 510(k) submission, and commercial coverage from Anthem Blue Cross Blue Shield effective July 2026. Distribution channels include direct enterprise sales, e-commerce for consumables, a global distributor network (e.g., Emocog for Korea), and strategic channel partners (Tempus AI for EHR-integrated ordering, Life Line Screening for community-based screening).

Recent corporate developments include the 2025 Akoya merger, the January 2026 appointment of Everett Cunningham as CEO, multiple 2026 commercial leadership hires (Jim Gute as CCO, Anthony Catalano as COO, Jason Faessler as CFO, Geoff Albrecht as SVP/GM Diagnostics), a sales force reorganization, and revised FY2026 revenue guidance of $142-148M following Q2 2026 commercial execution challenges. FY2025 revenue was $138.9M with a net loss of $107.2M.

Name

Quanterix

Legal name

Quanterix Corporation

Website

https://quanterix.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Short description

Quanterix is a publicly traded precision biomarker company (Nasdaq: QTRX) that develops Simoa digital immunoassay and Akoya spatial biology platforms to enable ultra-sensitive protein detection for pharmaceutical, academic, CRO, and clinical diagnostics customers across research and Alzheimer's disease testing.

Ownership category

akta.pro rank

Product category

Biomarker Detection Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)

akta.pro secondary industries

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB)

Keywords

• Biomarker detection
• Digital immunoassay
• Spatial biology
• Proteomics instruments
• Clinical diagnostics

Headquarters

HQ city

Billerica

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Instruments/Systems: Sale of Simoa instruments (HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System) and spatial biology instruments (PhenoImager HT, PhenoCycler-Fusion). Revenue recognized at time of shipment.
2. Consumables and Reagents: Recurring revenue from assay kits, reagents, and consumables. The company notes approximately 75% of revenue is in a recurring revenue profile driven by consumables sales.
3. Laboratory Services: Accelerator Laboratory provides biomarker research services, custom assay development, and clinical sample testing. Revenue recognized as services are completed.
4. Field Services: Service contracts and demand service for instrument maintenance and support, invoiced at start of coverage period or date of service performance.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Quanterix develops, manufactures, and sells ultra-sensitive digital immunoassay instruments (Simoa HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System) and spatial biology instruments (PhenoImager HT 2.0, PhenoCycler-Fusion 2.0), along with proprietary assay kits, reagents (including Nova Beads), laboratory services through its Accelerator Laboratory, and clinical diagnostic tests such as the LucentAD Complete blood test for Alzheimer's disease detection. The company's offering is built around its proprietary Simoa (Single Molecule Array) technology, which detects protein biomarkers at concentrations up to 1,000 times more sensitive than conventional ELISA methods, and its combined spatial biology platform acquired through the 2025 merger with Akoya Biosciences.

Product overview

Quanterix is a precision biomarker science company offering a dual-modality platform combining ultra-sensitive Simoa liquid biomarker detection with Akoya spatial biology tissue analysis. The core Simoa technology powers a portfolio of instruments (HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System), assay kits and reagents, and clinical diagnostics (LucentAD Complete). Akoya spatial biology offerings include PhenoImager HT 2.0, PhenoCycler-Fusion 2.0, PhenoImager Fusion instruments, along with PhenoCode Discovery panels (IO60 Protein, Human Neurobiology, Mouse Immuno-Oncology, Mouse Neurobiology), PhenoCode Signature Panels, and supporting software (phenoptr, phenoptrReports, inForm, Phenochart). The company operates an Accelerator Laboratory providing contract research and custom assay development services.

Differentiator

Problem solved

Functional benefit

Brands

• Lucent Diagnostics: Brand focused on bringing p-Tau testing to the clinic with the LucentAD blood test for Alzheimer's disease diagnostics
• Simoa
• LucentAD
• PhenoImager
• Akoya PhenoCycler-Fusion
• Simoa Accelerator Laboratory
• Content Innovation Engine

Products and services

• Simoa HD-X Analyzer

Quantifiable outcome

• Multi-analyte algorithm reduced diagnostic ambiguity by approximately 3-fold compared with standalone plasma p-Tau217 in published study
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Partnerships

Eight partnerships are on record, tiered major, core and minor.

• ALZpathmajorTechnology or Integration · 13 July 2026ALZpath's proprietary pTau217 antibody licensed to Quanterix for development of research and clinical pTau217 diagnostic assays. Antibody featured in 219 peer-reviewed publications and selected by major diagnostics companies including Abbott, Roche, Siemens Healthineers.
• Tempus AI Inc.coreStrategic or Co-development Partner · 15 May 2026Integration of LucentAD Complete Alzheimer's biomarker panel into Tempus Next AI-enabled care pathway platform. Enables neurologists to order multi-biomarker tests directly through Tempus clinical ordering platform and existing EHR systems, aiming to narrow diagnosis gap for the 7+ million Americans living with Alzheimer's.
• PreludeDxminorStrategic or Co-development Partner · 17 April 2026Collaboration to develop AidaBREAST, the first multi-omic assay predicting both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, validated on Quanterix's PhenoImager HT platform.
• Emocog Inc.coreChannel Partner/ Reseller/ Distributor · 1 March 2026Exclusive distribution agreement bringing Quanterix's Simoa blood-based biomarker platform for Alzheimer's detection to Korea. Emocog will supply tests at affordable prices and is targeting formal in vitro diagnostic approval in Korea within the year, leveraging the country's advanced diagnostics ecosystem and digital literacy.
• Life Line ScreeningcoreChannel Partner/ Reseller/ Distributor · 1 March 2026Partnership to offer non-invasive blood-based biomarker tests nationally through Life Line Screening's network of over 15,000 community events annually across Florida, California, and Texas. Expands access to diagnostic testing outside clinical settings for early detection of chronic conditions including Alzheimer's disease.
• Emocog Inc. (Korea)coreChannel Partner/ Reseller/ Distributor · 14 December 2025Exclusive distribution agreement for Quanterix-Lucent Diagnostics products in Korea, bringing ultra-sensitive Alzheimer's blood test platform to the Korean market targeting in vitro diagnostic approval.
• Akoya BiosciencescoreTechnology or Integration · 25 July 2025$286 million merger with Akoya Biosciences completed in 2025, adding multiplexed tissue imaging and 1,396 installed instruments to Quanterix's portfolio. Combined platform enables dual modality biomarker analysis across blood and tissue.
• Alzheimer's Drug Discovery Foundation (ADDF)majorStrategic or Co-development Partner · 29 March 2022Partnership to develop multi-analyte plasma test for early Alzheimer's detection. ADDF funding clinical trials in collaboration with Amsterdam University Medical Centers to validate the test for clinical use.

Scale indicators10 records

Recent moves7 records

Expansion highlights8 records

Direct peers

• Bio-Techne: Bio-Techne is a direct peer offering life science research tools including immunoassay reagents, ELISA kits, and protein detection instruments. Both companies serve pharma/biotech and academic researchers with biomarker detection technologies, with Bio-Techne's Simple Western and Ella platforms overlapping Quanterix's Simoa value proposition.
• Meso Scale Diagnostics (MSD): MSD is a direct competitor in ultrasensitive immunoassays, offering electrochemiluminescence-based multiplex platforms (Meso QuickPlex, U-PLEX, S-PLEX) that compete with Simoa for biomarker detection applications. Both companies target pharma, biotech, and academic customers for ultra-sensitive protein quantification.
• Standard BioTools (formerly Fluidigm): Standard BioTools is a direct peer in spatial biology and high-plex tissue imaging following the Akoya merger. Both companies offer spatial proteomics platforms (Standard BioTools' Hyperion Imaging System vs. Quanterix's PhenoImager HT/PhenoCycler-Fusion) for single-cell-resolution tissue biomarker analysis.

Broad incumbents

• 10x Genomics: 10x Genomics is a broad incumbent in single-cell and spatial biology with Xenium and Visium platforms. The company competes with Quanterix's Akoya-derived spatial biology offerings in tissue-based multi-omic analysis, though with broader portfolio reach into genomics and single-cell sequencing.
• Roche Diagnostics: Roche is a broad incumbent diagnostics player with the Elecsys pTau217 Alzheimer's assay and a global hospital sales infrastructure. Roche's broader IVD menu and existing neurology sales channels position it as a primary competitive threat to LucentAD Complete upon commercial launch.
• Abbott Diagnostics: Abbott is a broad incumbent that has licensed the ALZpath pTau217 antibody for its own Alzheimer's diagnostic assay (ARCHITECT and Alinity platforms). Abbott's established clinical lab customer base and global commercial reach represent a significant competitive threat to Quanterix's blood-based Alzheimer's franchise.
• Siemens Healthineers: Siemens Healthineers has also licensed the ALZpath pTau217 antibody for its AD-Detect Alzheimer's assay on the Atellica platform. As a major IVD incumbent with established clinical relationships, Siemens competes head-to-head with LucentAD Complete for blood-based Alzheimer's testing market share.
• Revvity (formerly PerkinElmer Life Sciences): Revvity operates a broad life sciences portfolio including immunoassay platforms, reagents, and imaging systems. Comparable to Quanterix across multiple touchpoints including diagnostics reagents, analytical instruments, and clinical diagnostics offerings through its EUROIMMUN and other acquired brands.
• Bruker Corporation: Bruker is a broad incumbent in scientific instruments including mass spectrometry and proteomics tools that compete in adjacent biomarker detection applications. The connection is broader — Bruker's new CFO Jason Faessler joined Quanterix from Bruker — and both serve pharma/biotech analytical workflows.

Emerging players

• NanoString Technologies: NanoString is an emerging player in spatial biology with the GeoMx Digital Spatial Profiling and CosMx SMI platforms. The company is comparable to Quanterix's Akoya-derived spatial biology business, though operating with narrower installed bases in research/translational settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/QuanterixSimoa
• Facebookfacebook.com/Quanterix
• LinkedInlinkedin.com/company/quanterix

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds12 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quanterix